In recent years, tumour immunotherapy has shown great promise especially in hematological malignancies. However, in solid tumours, there remain many hurdles to overcome to benefit the majority of patients.

Such challenges include how to penetrate physical barriers and deliver immunotherapeutic agents exactly to the tumour, and how to alter the immunosuppressive tumour microenvironment so that immunotherapeutics can take effect. In addition, it is worth exploring novel therapeutics. Cancer immunotherapy will remain the hotspot of cancer research in the years to come and holds the promise of defeating cancer in the future.

This Special Issue welcomes submissions that highlight recent advances in cancer immunity and immunotherapy that hold clinical implications. Original research and review articles are welcome.

Potential topics include but are not limited to the following:

• Modifications of T and B lymphocytes for therapeutic purposes (clinical or pre-clinical)
• Targeting tumour stromal cells (tumour microenvironment) for cancer immunotherapy
• Methods to delay and/or reverse T cell exhaustion
• Checkpoint blockage therapies: novel checkpoints that hold therapeutic potentials or ways to improve existing checkpoint blockage therapies
• The applications of CRISPR-Cas9 in cancer immunotherapy, such as TCR and/or CAR modifications
• Clinical studies on tumour immunotherapy